2. Signaling Pathways
  3. Metabolic Enzyme/Protease
    Vitamin D Related/Nuclear Receptor
  4. RAR/RXR
  5. RXRβ Isoform

RXRβ

NR2B2

RXRβ Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-163436
    F44-A13
    		Antagonist
    F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders.
  • HY-114071
    BMS270394
    		Agonist 98.0%
    BMS270394 is a nuclear retinoic acid receptor (RAR-γ) agonist with the EC50 values of 30 nM and 400 nM for humanRAR-γ and RAR-β, respectively.
  • HY-120875
    HX600
    		Agonist ≥99.0%
    HX600 is a synthetic agonist for RXR (Retinoid X Receptor) heterodimer complex. HX600 prevents ischemia-induced neuronal damage. HX600 has orally bioactivity.
  • HY-U00449A
    AGN 193109 sodium
    		Antagonist
    AGN 193109 sodium is the sodium salt form of AGN 193109 (HY-U00449). AGN 193109 sodium is the pan antagonist for retinoic acid receptor (RAR), with Kd of 2, 2 and 3 nM, for RARα, RARβ and RARγ, respectively. AGN 193109 sodium reverses TTNPB-induced morphology changes and all-trans retinoic acid (tRA)/9-cis RA/13-cis RA-induced proliferation suppression in ECE16-1 cell. AGN 193109 sodium is the antidote for retinoic acidosis, that ameliorates the skin and mucosal toxicity.